| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1105330461 |
| P356 | DOI | 10.1186/S13075-018-1634-8 |
| P932 | PMC publication ID | 6034317 |
| P698 | PubMed publication ID | 29976231 |
| P50 | author | Michelle A. Petri | Q67485110 |
| Rosalind Ramsey-Goldman | Q67485111 | ||
| Murray B Urowitz | Q85245743 | ||
| Karen H Costenbader | Q87706447 | ||
| April M Jorge | Q89432321 | ||
| Ann E Clarke | Q90832496 | ||
| Cynthia Aranow | Q91409089 | ||
| Anca Askanase | Q91519987 | ||
| Sung Lim | Q93065549 | ||
| Ronald B. Melles | Q111076710 | ||
| P2093 | author name string | Lucy H Young | |
| John M Esdaile | |||
| Na Lu | |||
| Yuqing Zhang | |||
| Hyon Choi | |||
| Sharan K Rai | |||
| P2860 | cites work | Hydroxychloroquine-related retinal toxicity | Q26782822 |
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | Q33284736 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women | Q33976159 | ||
| Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 | ||
| Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence | Q36240425 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases | Q37622345 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. | Q38352048 | ||
| Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis | Q38758477 | ||
| Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). | Q39907371 | ||
| Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice | Q41564952 | ||
| The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal | Q41915573 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy | Q41920001 | ||
| Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials | Q41921005 | ||
| Therapies for active rheumatoid arthritis after methotrexate failure | Q41925478 | ||
| Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. | Q41929433 | ||
| Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study | Q41935248 | ||
| Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus | Q41935707 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Update on Screening Recommendations for Hydroxychloroquine Retinopathy | Q46402546 | ||
| The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both | Q46429861 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Lower kidney allograft survival in African-Americans compared to Hispanic-Americans with lupus | Q46849270 | ||
| Hydroxychloroquine: lean body weight dosing | Q47351651 | ||
| Additive Interaction in Survival Analysis | Q57167120 | ||
| Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates | Q64111108 | ||
| The gathering storm: hydroxychloroquine retinopathy screening in the U.K. | Q88236740 | ||
| Hydroxychloroquine Screening Alert: Change is in the Wind | Q89270436 | ||
| P433 | issue | 1 | |
| P921 | main subject | hydroxychloroquine | Q421094 |
| P304 | page(s) | 133 | |
| P577 | publication date | 2018-07-05 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines | |
| P478 | volume | 20 |
| Q90476591 | Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine |
| Q99418451 | An objective method of diagnosing hydroxychloroquine maculopathy |
| Q93180376 | Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics |
| Q94529479 | Guide for Nuclear Medicine Applications During the COVID-19 Outbreak |
| Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
| Q99552022 | Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy |
Search more.